Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice

小鼠原发性 RSV 感染的溶细胞 T 细胞活性

基本信息

项目摘要

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and small children. RSV infection in mice is characterized by significant immunopathology which is mediated by CD8+ cytotoxic T lymphocytes (CTL). Past studies have suggested that CD8+ T cells with different functional properties and characteristics can be elicited following infection or immunization, and may have differential effects on viral clearance and RSV-associated illness. We have described differences between neonatal and adult CD8+ T cell responses elicited during RSV infection. Differences in clonotype, functional avidity, and other intrinsic parameters of the CD8+ T cell response may help dictate the epitope hierarchy established following infection. We have now defined the dynamics of lung-migratory dendritic cell populations in the lung and lung-draining lymph nodes of RSV-infected mice during early life as compared to adulthood and have determined lung dendritic cell populations that induce RSV-specific adaptive T cell responses following infection. These dendritic cells were found to induce T cell responses in an age-dependent manner, and we have implicated lower costimulatory molecule expression by neonatal dendritic cells as one mechanism for this difference. Our work in the last year has been greatly aided by the development and characterization of three strains of transgenic mice with CD8+ T cells specific for RSV. Continued work on this study will fully characterize CD8+ T responses to RSV, elucidate important factors that dictate the type of CD8+ T cell response that is generated, and help understand how other cell types regulate the CD8+ T cell response in an age-dependent fashion.
呼吸道合胞病毒(RSV)是婴幼儿下呼吸道感染的主要原因。RSV感染小鼠的特征在于由CD8+细胞毒性T淋巴细胞(CTL)介导的显著免疫病理学。过去的研究表明,具有不同功能特性和特征的CD8 + T细胞可以在感染或免疫后被诱导,并且可能对病毒清除和RSV相关疾病具有不同的作用。我们已经描述了新生儿和成人之间的差异引起的RSV感染的CD8 + T细胞反应。CD8 + T细胞应答的克隆型、功能性亲合力和其他内在参数的差异可能有助于决定感染后建立的表位层次。我们现在已经确定了与成年期相比,RSV感染小鼠早期肺和肺引流淋巴结中肺迁移树突状细胞群体的动态,并确定了感染后诱导RSV特异性适应性T细胞应答的肺树突状细胞群体。 发现这些树突状细胞以年龄依赖性方式诱导T细胞应答,并且我们已经将新生树突状细胞较低的共刺激分子表达作为这种差异的一种机制。 我们去年的工作得到了三种具有RSV特异性CD8 + T细胞的转基因小鼠品系的开发和表征的极大帮助。这项研究的继续工作将充分表征CD8 + T细胞对RSV的反应,阐明决定产生的CD8 + T细胞反应类型的重要因素,并帮助了解其他细胞类型如何以年龄依赖性方式调节CD8 + T细胞反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Barney Graham其他文献

Barney Graham的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Barney Graham', 18)}}的其他基金

Cellular Immune Responses to RSV infection in Mice
小鼠对 RSV 感染的细胞免疫反应
  • 批准号:
    10273005
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
Rapid Development of Vaccines for Emerging Viruses
新兴病毒疫苗的快速开发
  • 批准号:
    10497747
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
Coronavirus vaccine development
冠状病毒疫苗开发
  • 批准号:
    9551285
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV
RSV 发病机制中导致免疫增强性疾病的因素
  • 批准号:
    7964834
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
Vectors and Methods to Increase Immunogenicity during DNA Vaccination
DNA 疫苗接种过程中提高免疫原性的载体和方法
  • 批准号:
    7964850
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
HIV Preventive Vaccine Studies
HIV预防疫苗研究
  • 批准号:
    7964840
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
Vaccine Studies in HIV-infected Subjects
HIV 感染者的疫苗研究
  • 批准号:
    8148436
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
HIV Preventive Vaccine Studies
HIV预防疫苗研究
  • 批准号:
    8148433
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV
RSV 发病机制中导致免疫增强性疾病的因素
  • 批准号:
    8336383
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice
小鼠原发性 RSV 感染的溶细胞 T 细胞活性
  • 批准号:
    8556100
  • 财政年份:
  • 资助金额:
    $ 64.55万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 64.55万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 64.55万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 64.55万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 64.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 64.55万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 64.55万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 64.55万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 64.55万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 64.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 64.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了